Reality Check For Real World Data: FDA’s Sentinel Network Enters “Production” Stage
This article was originally published in RPM Report
FDA’s Sentinel drug safety surveillance network has completed an important transition, moving from “experimental” to “production stage” as a tool to help inform post-market safety decisions. Now the question is whether real-world data can be used in making efficacy decisions.
You may also be interested in...
US FDA’s David Martin encourages sponsors to register observational studies on drug effectiveness to enhance transparency and agency confidence in the data.
PDUFA reauthorization agreement sets up fiscal 2020 as milestone for weaving active surveillance into drug review – and for keeping sponsors informed of activities that affect their products.
The Sentinel post-marketing surveillance system is up and running. Now, FDA is ready to explore uses beyond safety.